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Abstract
Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. 
Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic 
kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific 
and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further 
advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the 
survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD 
requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and 
CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert 
panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management 
of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement 
treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is 
the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of 
this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, 
HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis 
units, treatment of HCV infection and management of HCV in kidney transplantation.
Keywords HCV infection · Chronic kidney disease · Direct-acting antiviral agents · HCV in renal transplantation
Introduction
Chronic hepatitis C virus (HCV) infection is a leading cause 
of chronic liver disease and is now considered as a public 
health concern with a worldwide prevalence rate of 1–2%. 
HCV infection is associated with an increased morbidity and 
mortality secondary to hepatic injury and to the associated 
extrahepatic complications. Among these, kidney involvement 
is frequent and includes proteinuria, different types of glo-
merulonephritis, cryoglobulinemia and chronic kidney disease 
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(CKD). It is now widely accepted that HCV infection predis-
poses to the onset of CKD; moreover, it worsens the prognosis 
of renal patients by increasing the risk of ESRD and mortality 
in non-dialysis CKD patients, mortality rate in hemodialysis 
patients and loss of graft in kidney transplant recipients.
The knowledge of the HCV genome has permitted the 
development of new drugs, the so-called direct-acting anti-
viral agents (DAA) that can achieve much higher sustained 
virologic response rates than previous therapeutic regimens 
based on the use of interferon with or without ribavirin. From 
a renal perspective, these drugs have a double advantage: DAA 
can improve prognosis of patients with established CKD and, 
on the other hand, can effectively prevent the occurrence of 
CKD de novo. This latter point is particularly attractive as a 
primary preventive strategy aimed at controlling the epidemic 
growth of CKD worldwide and consequently at reducing the 
burden of CKD complications and associated costs.
Management of CKD patients with HCV infection obvi-
ously requires a multidisciplinary approach in order to appro-
priately select potential candidates to DAA therapy, identify 
the better drug combination and manage the occurrence of 
adverse effect of therapy. On this regard, the main scientific 
societies involved in the care of this high-risk population in 
Italy (Italian Association for the Study of the Liver-AISF, Ital-
ian Society of Infectious and Tropical Disease-SIMIT, Ital-
ian Society of Internal Medicine-SIMI and Italian Society of 
Nephrology-SIN) have decided to constitute a joint committee 
to produce the present position statement. Statements cover 
seven areas including epidemiology of CKD, HCV-induced 
glomerular damage, HCV-related renal risk, staging of liver 
disease in patients with CKD, prevention of transmission of 
HCV in hemodialysis units, treatment of HCV infection and 
management of HCV in kidney transplantation. This docu-
ment is not a formal guideline, but is intended as a support 
in the decision-making process of treatment of HCV infected 
patients carrying the whole spectrum of renal diseases, from 
conservative phase to renal replacement therapy (dialysis and 
transplantation). Therefore, the purpose of this position paper 
is to discuss some major controversial issues from different 
perspectives (nephrology, hepatology, infectivology, internal 
medicine, and gastroenterology) by providing reasoned state-
ments, which can support the management of CKD patients 
with HCV infection in the daily clinical practice. Sharing 
specific evidence-based expertise of different healthcare 
professionals is the first step to obtain a common ground of 
knowledge in which instate a model for multidisciplinary man-
agement of this population.
Epidemiology of chronic kidney disease: 
classification and prevalence
Statement 1.1  Cause of renal disease, estimated glomeru-
lar filtration rate (eGFR) and albuminuria 
are the three parameters for staging Chronic 
Kidney Disease (CKD). The same CKD 
classification, based on alterations of GFR 
and albuminuria persisting for > 3 months, 
can be adopted for general population and 
patients with HCV infection.
Rationale
CKD classification is based on three parameters: the cause 
of renal disease (glomerular, vascular, tubulointerstitial, 
cystic or congenital), renal function, and the presence of 
renal damage [1]. Abnormalities of renal function (esti-
mated by eGFR) and/or renal damage (testified by albu-
minuria, abnormalities of urinary sediment, altered renal 
histology demonstrated by renal biopsy, structural damage 
of kidney evidenced by renal imaging and history of renal 
transplantation) must persist for at least 3–6 months in 
order to define “chronic” the renal disease. Renal function 
is classified in six categories of eGFR and albuminuria in 
three categories defined as normal (A1), moderate (A2) 
and severe (A3) (Fig. 1). Albuminuria represents the most 
important marker of renal damage and the most powerful 
risk factor for progression of CKD. This means that an 
albuminuric patient will start dialysis well before than a 
non-albuminuric patient, even in the presence of similar 
age, gender, eGFR and comorbidities. Albuminuria can be 
assessed as daily excretion in 24 h urine collection or on 
a first morning void urine specimen, as ratio with urinary 
creatinine (albumin/creatinine ratio, ACR); this can be 
useful for non-nephrologists because it avoids the need of 
validating the correctness of 24 h urine collection. Inter-
estingly, urine dipstick can easily detect albuminuria and it 
can be used as screening strategy; if positive, the dipstick 
must be confirmed subsequently by quantitative laboratory 
measurement. Staging of CKD provides crucial informa-
tion also on the prognosis of CKD patients because global 
risk including death, cardiovascular (CV) events and end-
stage renal disease (ESRD) increases exponentially with 
eGFR decline and with increase in albuminuria category 
(Fig. 1) [1].
The ability of residual nephrons to compensate the renal 
impairment explains why CKD patients are frequently 
asymptomatic even in more advanced stages of disease. 
This intrinsic feature of CKD contributes to the scarce 
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awareness of CKD. Indeed, only 10% of patients with 
CKD had knowledge of their disease [2]. An unacceptably 
low awareness of CKD (16–17%) has been also detected 
among physicians [3, 4].
Classification of CKD, based on eGFR and albuminu-
ria, must be implemented also in CKD patients with HCV 
infection, due to the frequent association between these two 
diseases. An observational study in 24,642 subjects from 
general population in Taiwan has documented a prevalence 
of CKD about three-fold higher in patients with HCV infec-
tion with respect to those non-infected (16.5% versus 6.1%) 
and a prevalence twice of significant proteinuria (11.6% ver-
sus 5.0%) [5]. Similar findings were found in 552 patients 
HCV positive followed in a Gastroenterology clinic as com-
pared with 313 patients without infection matched for age, 
gender and race (9.6% versus 5.1%) [6]. The association 
between HCV infection and CKD is constantly growing in 
last years [7]. The most important caveat for CKD patients 
with HCV infection is related to the eGFR estimation in 
those who have cirrhosis. Indeed, cirrhotic patients have sev-
eral underlying conditions (decreased creatinine production 
secondary to decreased hepatic creatine synthesis and con-
version to creatinine, increased tubular creatinine secretion, 
and muscle wasting) that contribute to falsely low serum 
creatinine concentrations leading to overestimation of GFR. 
This is particularly true for Jaffé assay of creatinine, which 
is influenced by “non-creatinine” chromogens present in the 
plasma (typically bilirubin) more than enzymatic assay [8]. 
Therefore, as direct methods for GFR measurement (inulin 
clearance and other direct methods using injected exogenous 
radiolabeled substances) are impracticable in clinical prac-
tice, nephrologists and gastroenterologists need to be aware 
that creatinine measurements overestimate renal function in 
patients with cirrhosis, and what may appear to be relatively 
small increases represent much larger changes in eGFR. As 
such, creatinine results should be interpreted cautiously in 
cirrhotic patients taking into account age, sex, degree of liver 
impairment and muscle mass. This aspect has two important 
clinical consequences: first, creatinine is included in the 
model for end-stage liver disease (MELD) score used for 
liver transplant allocation and, second, the selection of DAA 
regimen and monitoring of renal function during treatment is 
usually based on creatinine-based eGFR estimates.
Statement 1.2  The prevalence of CKD in the Italian gen-
eral population is about 7%.
Rationale
Previous studies reported estimates of CKD in general popu-
lation varying from 6.4 to 12.7% [9] likely due to the het-
erogeneity of study design, such as differences in population 
sampling, age, extent of geographic area, equation used to 
estimate eGFR and examined stages. The cardiovascular risk 
profile in Renal patients of the Health Examination Survey 
(CARHES) study has provided more accurate data by show-
ing that the crude prevalence of CKD (95% confidence inter-
val) was 7.05% (6.48–7.65) in Italian general population. 
Early stages constituted 59% of the CKD patients [Stage 
G1–2 A2–3: 4.16% (3.71–4.61) and Stage G3–5: 2.89% 
(2.51–3.26)]. CKD prevalence slightly decreased after age 
standardization to the resident population (overall: 6.7%) 
(Fig. 1) [2]. We can therefore estimate that, in Italy, there is 
a total number of 2.180.542 adult persons (age 35–79 years) 
with CKD (49.3% males), most with early disease (60.4%) 
and older age (69.8%). An ACR of ≥ 30 mg/g was detected 
in 4.77% of subjects. In particular, ACR was moderate (ACR 
30–300 mg/g, formerly defined as microalbuminuria) in 
84.3% of albuminuric persons, with the remaining 15.7% 
having severe albuminuria (ACR > 300  mg/g, formerly 
defined as macroalbuminuria). At multivariate regression 
analysis, age, obesity, hypertension, diabetes, CV disease 
and smoking were all independent correlates of CKD [2].
CKD has a lower prevalence in Italy, in particular for 
advanced stages, when compared with similar national sur-
veys outside Europe (13.1% in US, 12.5% in Canada, 11.5% 
Fig. 1  CKD Classification 
proposed by KDIGO Guidelines 
and estimated age-standardized 
prevalence (%) in Italian general 
population [2]. Colors refer 
to global prognosis accord-
ing to KDIGO Guidelines [1]: 
green, low risk (in absence of 
other markers of renal disease, 
patients do not have CKD); yel-
low, risk moderately increased; 
orange, high risk; red, very-high 
risk. (Color figure online)
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in Australia) [9]. This occurs despite older age and unfavora-
ble CV risk profile of the whole population. Therefore, it has 
been hypothesized that features inherent to the population 
living in Italy may be protective for CKD development, even 
in the presence of negative risk profile. Whether this is a 
‘renal’ aspect of the genetic low background risk [10], and/
or dependent on the still high adherence to the Mediterra-
nean diet [11, 12], deserves further studies.
Statement 1.3  People with CKD must be considered at 
increased risk for mortality, cardiovascular 
disease, progression to advanced CKD and 
hospitalization.
Rationale
CKD population is exposed to a high risk of morbidity and 
mortality due to several metabolic and hormonal dysfunc-
tions and hydro-electrolyte abnormalities that negatively 
affect prognosis. Indeed, besides traditional risk factors com-
mon to the general population, renal patients experience sev-
eral CKD-dependent complications (such as hypertension, 
anemia, secondary hyperparathyroidism, oxidative stress, 
and malnutrition among others) that increase exponentially 
the renal and CV risk of this population thus explaining why 
CKD is now considered a “disease equivalent” of diabetes 
mellitus [13, 14]. Staging CKD by eGFR and albuminuria 
is of paramount importance to optimize risk stratification in 
this population (Fig. 1).
Prognosis of CKD patients in Italy has been evaluated 
by the TArget Blood pressure LEvel (TABLE) cohort 
study in 1248 patients with CKD stage 3–5 (GFR < 60 mL/
min/1.73 m2), steadily followed from 2003 to 2010 in 25 
Nephrology clinics in Italy [15–17]. Risk factors more 
frequently recorded in such population were hypertension 
(88%), dyslipidemia (58%), proteinuria (52%) and anemia 
(27%) [15]. TABLE study evidenced an incidence of ESRD 
of 8.3 per 100 patients-year (95% CI 7.4–9.2) and of all-
cause death of 5.9 per 100 patients-year (95% CI 5.2–6.6) 
[16]. Besides age, history of CV disease, anemia and hyper-
phosphatemia, proteinuria was the most powerful risk fac-
tor predicting progression of renal disease in patients with 
eGFR 15–60 mL/min/1.73 m2 while in the more advanced 
stage (eGFR < 15 mL/min/1.73 m2) proteinuria was not 
associated with the risk of ESRD [16]. Adverse outcomes 
associated with proteinuria were evident in both younger 
and older patients (> 75 years) [17]. The cause of renal dis-
ease also plays an important prognostic role [18]. Indeed, 
patients with diabetic nephropathy or autosomal polycys-
tic kidney disease as primary renal disease have a risk of 
ESRD two- and five-fold higher, respectively; this holds true 
independently from the achievement of optimal control of 
those risk factors (proteinuria, hypertension and anemia) that 
induce a faster decline of renal function [18]. Several obser-
vational studies have reported a strong association between 
pre-existing CKD and the risk of hospitalization. Cardiac 
disease, hypertension and infection were the most frequent 
primary causes of hospitalizations whereas progression of 
CKD and acute kidney failure were the most common sec-
ondary cause of hospitalization [19]. Go et al. reported an 
independent, graded association between GFR and the risk 
of hospitalization in 1,120,295 adults within a large, inte-
grated system of health-care delivery with at least one cre-
atinine measurement between 1996 and 2000 [20]. Indeed, 
age-standardized incidence rate of hospitalizations increased 
exponentially from 13.5 per 100 person-year in subjects with 
eGFR > 60 mL/min/1.73 m2 to 144.6 per 100 person-year 
in patients with eGFR < 15 mL/min/1.73 m2; after multi-
ple adjustments, hospitalization risk increased from 14% in 
stage G3a, up to 315% in stage G5 [20]. In addition, CKD 
patients were also more exposed to the risk for hospitaliza-
tion with infections [21], longer hospital stay and higher risk 
of readmission [22].
Statement 1.4  Patients with HCV infection are more pre-
disposed to develop Acute Kidney Injury.
Rationale
Severity of acute kidney injury (AKI) can be graded in three 
stages based on the entity of creatinine increase and uri-
nary output. AKI grade 1 is characterized by a creatinine 
increase between 50 and 100% of baseline value or by an 
absolute increase ≥ 0.3 mg/dL associated with oliguria (diu-
resis < 0.5 L in 12 h). In the grade 2, creatinine increases 
2–3 times the baseline level and oliguria persists for > 12 h; 
finally, AKI grade 3 is classified by either a serum creatinine 
3 times higher than baseline, or an increase to ≥ 4.0 mg/
dL or initiation of renal replacement therapy and anuria for 
more than 12 h [23].
As previously described for CKD, albuminuria plays a 
major role also for stratifying the risk of AKI. Indeed, a 
meta-analysis of 13 studies involving about 1.3 millions of 
patients, has evidenced that the risk of AKI progressively 
increased not only with eGFR decline (from 1.6 when eGFR 
is 60–74 up to 10.7 when eGFR < 15 mL/min/1.73 m2) 
but also in the presence of increasing albuminuria (from 
1.6 when ACR is 10–29  mg/g up to 4.0 when ACR is 
> 300 mg/g) [24]. For each eGFR category, the implemen-
tation of ACR improves risk stratification. As an example, 
a non-diabetic patient with eGFR in the range 45–59 mL/
min/1.73 m2 has a risk of developing AKI varying from 
2.72 in the absence of albuminuria up to 7.4 and 14.1 in the 
presence of moderate and severely increased albuminuria, 
respectively [24].
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Patients with HCV infection are more prone to develop 
AKI represented by either a renal functional involvement or 
acute tubular necrosis. In a retrospective analysis of the US 
Nationwide Inpatient Sample of the Healthcare Cost and 
Utilization Project, 4,603,718 adult hospitalizations with an 
associated HCV diagnosis from 2004 to 2012 in the US were 
identified. The proportion of HCV positive hospitalizations 
complicated by dialysis-requiring AKI increased signifi-
cantly from 0.86% in 2004 to 1.28% in 2012 [25]. In HCV 
infected patients, the presence of CKD was associated with 
an adjusted risk for AKI requiring dialysis (OR 2.17, 95% CI 
2.03–2.33) similar to that observed for chronic liver disease 
(OR 2.11) and greater than that associated with heart failure 
(OR 1.79), hypertension (OR 1.78) or diabetes (OR 1.10) 
[25]. In-hospital mortality was significantly higher in hos-
pitalizations complicated by dialysis-requiring AKI versus 
those without (27.38% vs. 2.95%; adjusted odds ratio 2.09, 
95% CI 1.74–2.51). The most important limitation of the 
study was the use of administrative data (ICD-9-CM codes) 
to define HCV infection.
In some studies in HIV infected populations [26, 27], the 
association between HCV co-infection and AKI remained 
significant in multivariate analysis. The pooled relative risk 
of AKI in patients with HIV-HCV co-infection was 64% 
higher than in those without HCV co-infection without 
significant heterogeneity [28]. However, another study in a 
cohort of HCV infected patients (n = 267), reported that HIV 
co-infection was related with AKI whereas HCV genotype 
and HCV viral load did not [29].
It is important to keep in mind that patients experienc-
ing an AKI episode not only were more prone to develop 
CKD or dialysis but they had a two-fold greater risk of 
mortality [30]. Even more suggestive were the data pro-
vided by Bucaloiu et al. [31]. In that study, 1610 patients 
with reversible AKI that resolved within 90 days after 
discharge were matched, using a propensity-score across 
multiple parameters, with 3652 control patients who had 
not experienced AKI [31]. Reversible AKI was associated 
with an 18% higher risk of death, and, more importantly, 
with a greater risk of de novo CKD (HR 1.91, 95% CI 
1.75, 2.09). This occurs likely because of the presence of 
renal fibrosis or tubulointerstitial injury induced by the 
AKI episode that in the long-term promotes chronicity of 
renal damage. Thus, a resolved episode of hospital-asso-
ciated AKI has important implications for the longitudinal 
surveillance of patients without preexisting, clinically evi-
dent renal disease. This concept applies to all categories of 
at-risk patients without preexisting CKD, including those 
with HCV infection, in which management strategies for 
primary CKD prevention become mandatory.
Statement 1.5  Timing of referral of CKD patients to neph-
rologist should be based on eGFR, albumi-
nuria and complications.
Rationale
The above-mentioned low CKD awareness translated 
in an insufficient referral to nephrology clinics even for 
patients with advanced CKD (only 55% of patients with 
GFR < 30 mL/min/1.73 m2 were referred to nephrologists) 
[4]. This low referral rate is associated with a greater risk 
of death and ESRD in comparison with patients regu-
larly followed in nephrology clinics [32]. Furthermore, 
delayed referral to nephrologists associated with higher 
mortality, increased risk of hospitalization, longer hospital 
stay, impaired metabolic status, worse anemia control and 
healthcare expenditures [22, 32–34].
Referral to nephrologists should be recommended when 
eGFR is below 30 mL/min/1.73 m2 independently from 
albuminuria level or in patients with severe albuminuria 
(category A3) independently from eGFR category [1]. 
However, earlier nephrology referral is indicated in the 
presence of CKD-specific complications (Table 1).
Table 1  Clinical and laboratory 
conditions requiring nephrology 
referral
a Defined as either ACR > 300 mg/g or 24 h albuminuria > 300 mg/day or 24 h proteinuria > 500 mg/day or 
Dipstick > 1
GFR < 30 ml/min/1.73 m2 (GFR categoriesG4-G5) independently from albuminuria level
Severe  Albuminuriaa, independently from eGFR
Rapid eGFR decline (> 5 mL/min/year or change of GFR category with at least 25% GFR reduction)
Hematuria
Resistant hypertension (defined as BP above target despite the use of ≥ 3 drugs including a diuretic)
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HCV infection and glomerular damage: 
pathogenetic‑laboratory data 
and histopathological aspects
Statement 2.1  All patients with glomerular disease (espe-
cially those with cryoglobulinemic nephri-
tis) should be screened for HCV infection.
Rationale
HCV infection is associated with a large spectrum of glo-
merular diseases and their clinical sequelae (Table 2). The 
most frequently observed is the cryoglobulinemic glomeru-
lonephritis (cryoglobulinemic nephropathy) secondary to 
type II mixed cryoglobulinemia (MC), and histologically 
characterized by Type 1 membranoproliferative glomerulo-
nephritis (MPGN) [35, 36].
Other nephropathies, including MPGN without cryoglo-
bulinemia, membranous nephropathy (MN) and mesangio-
proliferative glomerulonephritis, are rarely associated and 
only occasional observations exist describing focal segmen-
tal glomerulosclerosis, fibrillary or immunotactoid glomeru-
lopathies or thrombotic microangiopathy in HCV infected 
patients [37].
Statement 2.2  The pathogenetic mechanisms may be 
related indirectly and directly to the viral 
infection. The risk of measures leading to 
a rapid increase of viral replication and the 
consequent increase of viremia should be 
taken into account.
Rationale
The pathogenesis of HCV-related nephropathy has not yet 
been fully clarified, but several piece of evidence suggests 
the intervention of different mechanisms, either directly 
related to kidney infection or mediated by the host’s immune 
response. From this point of view, the kidney appears to have 
peculiar characteristics that make the study of HCV-related 
damage of special interest and potential translational value.
The role played by mechanisms secondary to the immune 
reaction of the host have been especially emphasized [38, 
39]. Above all, the latter appears to be represented by the 
effect of the production and deposition of circulating (more 
or less cryoprecipitating) immune complexes.
Nevertheless, the role played by the direct infection of 
cells (renal and/or lymphatic) has also been shown. In the 
MC, a combination of direct and indirect effects of the viral 
infection on the B-cell compartment leads to the clonal 
expansion of B cells producing RF (B RF cells), and the 
Table 2  Main HCV-Associated Kidney Diseases, clinical manifestations and suggested pathogenetic factors
MPGN membranoproliferative glomerulonephritis, MN membanous nephropathy, Ig immunoglobulin, TLR-3 toll-like receptor 3, MMP-2 matrix 
metalloprotease 2
Kidney disease Clinical manifestations Hypothetical pathogenetic factors
Cryoglobulinemic MPGN Nephritic syndrome, nephrotic syndrome Cryoglobulin deposition in glomerular capillar-
ies, mesangium, and urinary space; mesangial 
deposits of immune complexes including HCV 
antigens, Ig and complement
Non-cryoglobulinemic MPGN Nephritic syndrome, nephrotic syndrome Mesangial deposits of immune complexes (HCV 
antigens, Ig, and complement components)
MN Nephrotic syndrome Subepithelial deposits of immune complexes 
(HCV antigens, Ig, and complement compo-
nents)
IgA nephropathy Isolated proteinuria and/or hematuria Mesangial deposits of immune complexes (HCV 
antigens, Ig, and complements components)
Focal segmental glomerulosclerosis Nephrotic syndrome, Isolated proteinuria Direct injury by HCV on podocytes of epithelial 
cells
Immunotactoid glomerulopathy/ fibrillary 
glomerulonephritis
Nephrotic syndrome, Isolated proteinuria and/
or hematuria
Mesangial and capillary wall deposition of 
immune complexes (HCV antigens, Ig, and 
complement components)
Mesangial proliferative glomerulonephritis Isolated proteinuria and/or hematuria Direct effect of HCV on mesangium by TLR-3 or 
MMP-2
Tubulointerstitial nephritis Proteinuria HCV deposition in tubular epithelial and infiltrat-
ing cells (direct cytotoxicity and/or immune-
mediated injury)
Thrombotic microangiopathy Nephrotic syndrome, Isolated proteinuria and/
or hematuria
Endothelial injury by direct activity of HCV
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production of cryoglobulins, that exert pathogenetic effects 
on the kidney [35].
Therefore, the kidney appears to be an ideal model for 
expressing the HCV extrahepatic pathogenicity. In fact, its 
microstructure is suitable to examine the HCV-associated 
molecules, like cryoglobulins or other circulating immune 
complexes, antigens and antibodies. At the same time, it has 
been shown that the renal parenchyma expresses the main 
factors implicated in the various phases of HCV infection, 
such as LDL receptors, glycosaminoglycans, CD81 SR-B1 
receptors and TLR-3 [39]. In addition, it cannot be excluded 
that the virus enters the renal parenchyma also via a “Trojan 
Horse” mechanism, using either infected B cells [40] and/or 
exosomes [41]. Finally, kidney cells would be equipped with 
the cellular machinery required for replication. Concerning 
available data, HCV RNA has been found in mesangial cells, 
tubular epithelial cells, and endothelial cells of glomerular 
and tubular capillaries, and HCV-related protein depos-
its have been found in the mesangium [42, 43]. However, 
due to the technical difficulties in the evaluation of HCV 
viral infection in in vivo tissue samples (as a result of the 
rather high sensitivity of detection methods and the possible 
contamination by circulating particles), further studies are 
needed to better ascertain these data.
Special attention should be paid to cryoglobulinemic 
nephropathy. It is known that MC is a systemic vasculitis 
whose pathogenetic mechanisms are at the same time based 
on a lymphoproliferative disorder (remote pathogenesis) and 
circulating immune complexes (cryoglobulins) [44]. The 
systemic vasculitis resulting from this condition involves 
mainly small-sized arteries and veins and essentially derives 
from the deposition of immune complexes composed of RF, 
IgG, HCV RNA and complement on the endothelial surface. 
The histopathologic analysis in the case of cryoglobulinemic 
glomerulonephritis (see below) shows that cryoglobulins are 
deposited in the glomerular capillaries and mesangium. Fur-
thermore, there are usually histologic signs of vasculitis and 
downstream fibrinoid necrosis [39]. The nephrotoxicity of 
cryoglobulins deposited in the kidney is suggested to be sec-
ondary to affinity of IgM-RF for cellular fibronectin in the 
mesangial matrix [38, 45]. Cryoglobulins may also induce 
endothelitis via anti-endothelial activity and complement 
activation leading to the increased expression of VCAM-1 
and platelet aggregation [39].
Toll-like receptors (TLRs) may also have a role in 
HCV-associated renal injury. Interestingly, the glomerular 
expression of TLR4 (which is constitutively expressed by 
podocytes) and fibronectin was found to be upregulated in a 
murine model of cryoglobulinemic glomerulonephritis [46], 
and TLR3 expression was increased in mesangial cells of 
HCV-related MPGN patients [47].
The direct mechanisms of kidney damage may occur as a 
consequence of the active infection of cells and/or through 
the mere attachment of the virus to cell surface receptors, 
possibly inducing several direct cytopathic effects, that can 
be extrapolated in the kidney as endothelitis, mesangial 
inflammation and podocyte injury. The contribution of these 
more direct effects is supported by several observations. 
These include the fact that over 50% of the renal lesions 
occur in the absence of cryoglobulinemia, and a variable 
proportion without histological evidence of immune-medi-
ated injury. This is particularly evident in the immunocom-
promised patient, like the patient undergoing organ trans-
plantation (see below). In agreement with the hypothesis of 
direct pathogenic mechanisms, it has been reported a cor-
relation between levels of viral replication (as indicated by 
HCV viremia) and damage severity [48]. Despite the above-
cited technical limits, some studies have shown HCV repli-
cation in the renal tubules in patients with HCV-associated 
interstitial nephritis [49]. Furthermore, electron microscopic 
detection of viral like particles has been reported in renal 
biopsies, performed on HCV-infected patients [50, 51]. 
HCV-related virus-like particles were about 30–45 nm in 
diameter and located in electron-dense deposits in the para-
mesangial areas [51].
Statement 2.3  Testing serum cryoglobulins, complement 
and RF levels is useful for a correct diag-
nostic approach, even in patients without 
symptoms of cryoglobulinemic vasculitis.
Rationale
In the cryoglobulinemic nephropathy, renal biopsy typi-
cally shows a pattern of Type I MPGN and it is mostly 
associated with type II MC [52, 53] (see before). Cryo-
globulinemic nephropathy is characterized by the duplica-
tion of the glomerular basement membrane (GBM), GBM 
interposition by mesangial cells (especially monocytes), 
mesangial proliferation with leukocyte exudation, endo-
luminal hyaline pseudo-thrombi (corresponding to cryo-
globulin precipitates) and rarely extra-capillary prolifera-
tion. Immunofluorescence microscopy may reveal C3, IgM 
and IgG depositions on the capillary wall and mesangium. 
Intraluminal and subendothelial deposits may have a fibril-
lary pattern on electron microscopy likely representing 
cryoglobulin deposition [54]. In addition, one-third of 
these patients may have vasculitis in the small renal arter-
ies [35, 55, 56]. The laboratory shows typical markers of 
CM, with FR positivity, consumption of C4 component 
complement, with, obviously, positivity for HCV mark-
ers and positive cryocrit. Given the fluctuations in the 
cryocrit value and the difficulty of proper sampling, it is 
recommended to repeat the determination of cryoglobu-
lins after a negative result using stringent conditions [57]. 
692 Journal of Nephrology (2018) 31:685–712
1 3
Interestingly, in a large autopsy study, the glomerular dep-
osition of immune complexes was found also in patients 
without symptomatic glomerulonephritis [58].
If MPGN is the glomerular disorder most strongly asso-
ciated with chronic HCV infection, several cases of MN 
have been described in HCV infected patients [53, 59, 60]. 
The histological findings as well as the clinical presenta-
tion of HCV-associated MN are similar to the idiopathic 
form. Usually, serum complement levels are normal and 
cryoglobulins and RF are absent in the serum. There are 
several reports about the association between HCV and 
FSGS [61, 62] and IgA nephropathy [63–65].
Fibrillary-immunotactoid glomerulopathies may be 
associated with systemic disorders such as lymphopro-
liferative disorders, adenocarcinomas, connective tissue 
diseases and infectious diseases [66]. Six cases of fibril-
lary immunotactoid glomerulopathies associated with 
HCV infection have been described [67, 68]. Fibrillary 
and immunotactoid glomerulopathies are characterized by 
extracellular deposits of microfibrils within the mesan-
gium and glomerular capillary walls, which do not stain 
for Congo red [69]. Furthermore, immunofluorescence 
microscopy reveals IgG, especially IgG4, and C3 in the 
lesions [66]. On electron microscopy, fibrils with diame-
ters of 16–28 nm and 33–45 nm were observed in fibrillary 
glomerulonephritis and immunotactoid glomerulopathy, 
respectively [70].
Statement 2.4  Af te r  k idney  t ransp lan t a t ion  in 
HCV+ patients, the most frequent HCV-
associated nephropathy is MPGN (typically 
associated with cryoglobulinemia, hypoc-
omplementemia and/or RF).
Rationale
HCV-related glomerulopathy represents one of the most 
frequently reported HCV-associated adverse events after 
kidney transplantation [71–74]. MPGN was found to be the 
most common glomerulopathy (5–54% of cases) [75].
In a cohort of HCV-infected renal transplant recipients 
(n = 50), a greater rate of non-treated controls developed 
chronic allograft nephropathy compared with IFN-treated 
patients, 41% (13/32) vs. 6% (1/18), P = 0.009. According to 
a logistic regression analysis, the absence of antiviral ther-
apy before renal transplant was a risk factor for chronic allo-
graft nephropathy with an odds ratio of 12 (P = 0.02) [76].
Renal diseases occurring in HCV-infected patients after 
kidney transplantation include also MN, minimal change 
disease, renal thrombotic microangiopathy, FSGS, and acute 
and transplant glomerulopathies [75, 77]. Cryoglobulinemia, 
hypocomplementemia or RF were typically absent.
Hepatitis C virus infection and renal risk: 
acquisition and progression of chronic 
kidney disease
Statement 3.1  All patients who receive diagnosis of CKD 
should be screened for HCV infection.
Rationale
Testing for HCV appears logical in patients with CKD as 
several pieces of evidence support the notion that chronic 
HCV infection plays a role in the development of CKD. 
Prevalence and incidence rates of hepatitis C are more fre-
quent in patients with CKD (particularly, in those under-
going regular hemodialysis) than among those with nor-
mal kidney function [78]. Although controversial data exist 
[79], several observational studies have suggested that HCV 
favors the incidence or progression of CKD in the general 
population. A meta-analysis of observational studies (n = 9 
longitudinal studies; 1,947,034 unique patients) demon-
strated a relationship between positive anti-HCV serologic 
status and the incidence of CKD in the adult general popula-
tion that was 43% higher (HR 1.43, 95% CI 1.23–1.63) [80]. 
Significant heterogeneity was noted and this precluded more 
definitive conclusions. Based on current evidence, patients 
with HCV infection should be regarded as being at greater 
risk of CKD, regardless of the presence of conventional risk 
factors for kidney disease.
Statement 3.2  Screening for HCV infection should be 
made with enzyme immunoassay followed 
by nucleic acid testing. Non-dialysis CKD 
patients should be screened at the time of 
referral in outpatient clinic.
Rationale
Infection with HCV is characterized by increased serum lev-
els of alanine aminotransferase (ALT) in general population. 
However, blood testing for ALT has weak diagnostic value 
in renal patients, because in both maintenance hemodialy-
sis and non-dialysis CKD, ALT levels most commonly fall 
within the lower limit of normal range [81, 82]. The exact 
cause of this phenomenon is unclear and various agents have 
been cited: vitamin B6 deficiency, uremic toxins accumula-
tion and malnutrition. Detection of antibodies against HCV 
(anti-HCV) by the 4th-generation enzyme immunoassay 
(EIA) is the most commonly used screening tool for HCV 
infection [83]. Third-generation EIAs have high sensitivity 
(98.8%) and specificity (100%) [84, 85]. However, the time 
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between HCV infection and the appearance of detectable 
antibodies (serological window period) is generally more 
than 40 days using third generation EIAs [86]. In 2008, the 
4th-generation EIA has become available, which allows to 
detect the HCV antibody significantly earlier than the 
other assays [83]. A proportion of dialysis patients might 
test negative for anti-HCV, but test positive for persistence 
of viral particles (HCV-RNA) in the serum [87]. In fact, 
immune-compromised patients might either exhibit a delay 
in antibody production or an absence of specific antibod-
ies following acute HCV infection. Dialysis units with a 
high prevalence of HCV infection were estimated to have 
an 18% false-negative of anti-HCV test [87]. The Kidney 
Disease Improving Global Outcome (KDIGO) HCV Work 
Group had already recommended that all CKD patients be 
tested for HCV [88]; we suggest that in hemodialysis units 
initial testing by immunoassay should be considered; if posi-
tive, immunoassay must be followed by nucleic acid testing 
(NAT). Some issues such as frequent unavailability of test 
kits, costs, and limited reproducibility hamper NAT test-
ing. Recently, 2018 EASL recommended HCV core antigen 
detection and quantification by means of EIA when HCV 
RNA tests are not available and/or not affordable, as an alter-
native tool for early diagnosis of HCV infection [89].
Statement 3.3  All patients who receive diagnosis of HCV 
infection should be screened for kidney 
disease by using urinalysis and eGFR. If 
the initial screening for CKD is negative, 
patients with diagnosis of HCV infection 
and detectable HCV RNA should be tested 
for CKD on a regular basis (i.e., twice a 
year).
Rationale
CKD and HCV infection are connected in different ways [90, 
91]; HCV infection and CKD are prevalent in the general 
population of developed countries, patients on regular hemo-
dialysis are at risk of acquisition of HCV and some types of 
kidney disease are precipitated by HCV infection. On the 
other hand, conventional risk factors for CKD such as aging, 
diabetes mellitus, arterial hypertension, and metabolic syn-
drome do not fully explain the current frequency of CKD 
in the adult general population of developed world. Cohort 
studies performed either in patients with diabetes [92], or 
with biopsy-proven primary glomerulonephritis [93], or 
with HIV and HCV co-infection [28] have confirmed a sig-
nificant association between anti-HCV positive serologic 
status and development of CKD. In a pooled analysis of 
longitudinal studies (n = 8, with 105,462 unique patients) 
positive anti-HCV serologic status was associated with an 
increased risk of low eGFR among HIV-infected patients. 
The summary estimate for adjusted hazard ratio was 1.64 
(95% CI, 1.28–2.0, P < 0.001) in HIV-HCV co-infected 
patients compared with those having HIV mono-infection. 
No between-studies heterogeneity was found (P value by Q 
test = 0.08) [94].
The predictive role of HCV viral load on CKD has 
been evidenced recently in 13,805 Taiwanese participants, 
enrolled in the Risk Elevation of Viral Load Elevation 
and Associated Liver Disease/Cancer in HCV (REVEAL-
HCV) Study Group [95]. Compared to non-HCV-infected 
participants, the probability of having CKD in patients 
with chronic HCV infection significantly increased linearly 
across tertiles of HCV RNA (from 21 to 244% from lowest 
to higher tertile).
Of note, antiviral therapy for HCV consistently improves 
hepatic and extra-hepatic outcomes in the adult general pop-
ulation. Among liver transplant recipients with HCV who 
underwent antiviral therapy for HCV, sustained virologic 
response (SVR) led to improved eGFR in HCV-infected liver 
transplant patients with mild CKD before treatment [96]. 
Some studies, addressing the impact of interferon-based 
regimens on the development of CKD in the general popula-
tion, concluded that treatment of HCV might improve renal 
survival per se [6, 97–101]. The Taiwan National Health 
Insurance Research Database investigated the incidence 
of ESRD in 12,384 HCV-infected patients receiving anti-
viral therapy (pegylated interferon plus ribavirin) matched 
1:2 with 24,768 untreated patients over a follow-up of 
3.3 ± 2.5 and 3.2 ± 2.4 years, respectively. The calculated 
8-year cumulative incidence of ESRD accounting for death 
as a competing event, was 0.15% and 1.32% in treated and 
untreated patients, respectively (P < 0.001) [99]. Multivari-
ate-adjusted Cox regression revealed that antiviral treatment 
was associated with lower risks of ESRD (HR, 0.15; 95% 
CI: 0.07–0.31; P < 0.001) [99].
Statement 3.4  Patients with CKD and HCV infection 
should be evaluated with serial measure-
ments of eGFR and albuminuria over time 
to assess the progression of CKD.
Rationale
Besides cryoglobulinemic MPGN, HCV-infected individuals 
may also be at risk for kidney injury related to decompen-
sated cirrhosis, injection drug use, and concomitant HIV 
or HBV co-infection. Interestingly, recent evidences sug-
gest that HCV supports the development of atherosclerosis 
in various tissues and organs including kidneys. HCV can 
promote atherogenesis through several direct and indirect 
biological mechanisms including arterial inflammation, 
insulin resistance, liver steatosis, oxidative stress, hyper-
homocysteinemia, and greater production of tumor necrosis 
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factor-alpha [102–104]. All this findings support a close 
monitoring of renal damage over time (mainly by eGFR 
and albuminuria) in order to detect patients with earlier and 
faster progression of renal disease. Of note, a large obser-
vational cohort study involving more than one million of 
veterans, has evidenced that patients with positive to HCV 
(10% of cohort) had a doubled risk of starting dialysis and 
a 22% higher probability of having a faster progression of 
renal disease (GFR loss > 5 mL/min/year) [105].
Staging of liver disease in patients 
with chronic kidney disease
Statement 4.1  Liver biopsy should be considered only 
when clinically needed. A transjugular 
approach (instead of percutaneous tran-
sthoracic route) should be considered in 
selected circumstances.
Rationale
Although widely performed and established in diagnosing 
hepatic fibrosis, liver biopsy is an invasive technique with 
associated morbidity. The most common type of liver biopsy 
is a percutaneous liver biopsy; however, transvenous liver 
biopsy (transjugular or transfemoral route) is an alternative 
technique usually choiced in the presence of ascites, severe 
coagulopathy or thrombocytopenia contraindicating a percu-
taneous approach. Transjugular liver biopsy is also adopted 
when additional diagnostic data is needed (i.e., diagnosis of 
portal hypertension). CKD patients, and in particular ESRD 
individuals, frequently have significant hemostatic disorders 
and hemorrhagic complications, posing additional risks for 
patients undergoing invasive procedures [106]. Even with a 
normal INR and platelet count, percutaneous liver biopsy is 
not entirely safe due to platelet dysfunction associated with 
uremia. Recent evidence supports the pre-biopsy subcuta-
neous administration of desmopressin acetate (0,3 µg/kg) 
in CKD patients with serum creatinine ≥ 1.5 mg/dL (and/or 
eGFR ≤ 60 mL/min per 1.73 m2) as it decreases the risk of 
bleeding and hematoma size in patients undergoing percu-
taneous kidney biopsy [107]. Transjugular liver biopsy has 
been evaluated in the ESRD population and although it is 
safe, is not widely available and provides smaller samples 
than the intercostal route.
Statement 4.2  Non-invasive assessment of fibrosis stage 
by transient elastometry, AST to Platelet 
Ratio Index (APRI) and Fibrosis 4 (FIB-
4) score has been validated in patients with 
end stage renal disease. In patients with 
renal disease Fibrotest® is not an accurate 
predictor of fibrosis stage.
Rationale
Stage of liver fibrosis can be reliably predicted in ESRD 
HCV-infected subjects by simple and widely available blood 
tests such as AST levels and platelet count as a part of APRI 
or FIB-4 scores and have been validated in this population 
[108]. Transient elastometry (TE) is widely accepted as a 
reliable non invasive tool to assess the stage of liver dis-
ease in patients without renal disease. It has been confirmed 
that TE was superior to APRI in assessing the severity of 
hepatic fibrosis and can substantially decrease the need of 
staging liver biopsy in hemodialysis patients with chronic 
hepatitis C [109].  Fibrotest® and  Actitest® which have been 
validated as a non-invasive test for assessment of fibrosis and 
disease activity does not seem to be a reliable non-invasive 
marker in hemodialysis patients with HCV infection. This 
is probably due to alteration of apolipoprotein A-1 synthe-
sis in uremia and alpha-2 macroglobulin and haptoglobin 
alteration by acute phase reaction induced by the dialysis 
procedure [110].
Statement 4.3  Patients with liver stiffness measure-
ment > 9.2 KPa and/or with APRI > 0.8 
and or with FIB-4 > 3.25 should undergo 
semiannually screening for HCC by US 
and monitoring of liver function. Prognosis 
of liver disease in patients with advanced 
renal disease showing ascites as the only 
symptom of portal hypertension should be 
assessed also by measurement of Hepatic 
Venous Pressure Gradient.
Rationale
Liver stiffness FIB-4 and APRI cut offs with the best accu-
racy for the diagnosis of cirrhosis have been identified in 
patients with ESRD in a cross sectional study: they are 
respectively 9.2 kPa 0,8 and 3,25. Thus, screening for HCC 
and hepatic decompensation is mandatory in patients show-
ing transient elastometry and/or APRI or FIB-4 scores equal 
or below these values [109]. Ascites occurrence in patients 
with ESRD might be related to extrahepatic causes and prob-
ably occurs earlier in the course of liver disease in patients 
with advanced renal disease. Thus in patients where ascites 
is the only sign of liver decompensation, prognosis should be 
better assessed by Hepatic Venous Pressure Gradient evalu-
ation [111].
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Preventing transmission of hepatitis C virus 
infection in hemodialysis units
Statement 5.1  Infection control practices should include 
standard precautions and other patient-care 
procedures aimed at preventing transfer of 
blood (or fluids contaminated with blood) 
between patients, either directly or via con-
taminated equipment or surfaces. Infection 
control procedures within dialysis units 
should be reviewed on a regular basis with 
observational audits.
Rationale
The prevalence of HCV infection is still higher in patients 
undergoing maintenance dialysis than in the general popu-
lation (Table 3) [112–119]. Introduction of screening of 
blood (and blood products) for HCV and reduction in blood 
transfusion requirements following introduction of erythro-
poiesis-stimulating agent therapy has virtually eliminated 
the occurrence of post-transfusion HCV infection among 
patients on dialysis. Nosocomial transmission is currently 
the most likely source when hemodialysis patients develop 
anti-HCV antibody. Its occurrence has been highlighted by 
several epidemiological findings, such as the relationship 
between frequency of HCV infection and time spent on 
dialysis treatment, higher prevalence of HCV in hemodi-
alysis than peritoneal dialysis or home hemodialysis, and the 
highly variable prevalence of HCV from unit to unit [120].
Transmission of HCV occurs easily through parenteral 
route and its control is therefore a challenge in dialysis 
units. The occurrence of nosocomial transmission of HCV 
in hemodialysis units has been confirmed using molecular 
virology by various authors who identified clusters of closely 
related isolates of HCV by means of phylogenetic analysis, 
both in studies of individual units with high seroconversion 
rates and in multicenter studies. Parts of the HCV genome 
(especially hypervariable region 1) are highly variable and 
lend themselves to fingerprinting of each isolate or quasi-
species using nucleic acid sequencing [88].
The most likely source of HCV transmission between 
patients treated in the same dialysis unit is cross-contami-
nation from supplies and surfaces (including gloves) because 
of failure to follow infection-control procedures within the 
unit. Transmission via the internal pathways of the dialy-
sis machine has been cited in a few circumstances. Other 
possible transmission routes are direct contact between the 
patients, common infected blood donor, invasive procedures 
outside the unit with contaminated material used for both the 
source and the newly infected patient, and holiday dialysis 
in developing countries.
Some systematic reviews have analyzed the mechanisms 
of nosocomial transmission of HCV within dialysis facilities 
[88, 120, 121]. The conclusion was that the identification 
of the sources of de novo HCV infection is difficult due to 
several reasons, such as the asymptomatic nature of HCV 
infection, the long latency period of HCV infection, the lack 
of details in the dialysis treatment records, and the retro-
spective nature of the investigations addressing the sources 
of HCV spread within dialysis units. In addition, patients 
on maintenance dialysis undergo multiple treatments per 
week- this hinders the identification of source patients in 
dialysis outbreaks. A systematic review of 36 studies using 
molecular virology to address outbreaks of HCV infection 
within hemodialysis units provided evidence of nosocomial 
transmission of HCV within hemodialysis units [120].
Infection control procedures against transmission of 
blood-borne pathogens (including HCV) include Stand-
ard Precautions and other patient-care procedures which 
have been recommended for all hemodialysis patients since 
1977 [122]. Standard precautions are adopted in all inpa-
tient hospital settings, and include use of gloves, gowns, or 
masks whenever needed to reduce the risk of transmission 
of blood-borne and other pathogens from both recognized 
and unrecognized sources. Other precautions are unique 
to the hemodialysis setting and have been reiterated by the 
Centers for Disease Control and Prevention (CDC) in 2001 
[123] and later [124], regardless of the patient’s serological 
status (Table 4).
There are no RCTs evaluating the impact of regular audits 
on transmission of HCV infection within dialysis units. 
Some observational studies reported that implementing reg-
ular audits as part of quality improvement programs results 
in lowered rates of bloodstream infections [125]. However, 
the goal of these audits was the control of bloodstream 
Table 3  Prevalence of anti-HCV antibody positive serologic status 
among patients on maintenance hemodialysis (high- and low-income 
countries)
Author [reference] Prevalence of anti-
HCV antibody
Country Year
Alashek W [111] 31.1% (2382/7659) Libya 2012
Garcia-Agudo [112] 5.6% (708/12,472) Spain 2013
Goodkin [113] 3.3% (85/2575) UK 2013
Goodkin [113] 8.6% (1766/20,534) US 2013
Goodkin [113] 16% (413/2581) Italy 2013
Goodkin [113] 16.8% (1278/7607) Japan 2013
Ummate [114] 15% (15/100) Nigeria 2014
Lioussfi [115] 59.7% (40/67) Morocco 2014
Vidales-Braz [116] 18.2% (58/318) Brazil 2015
Duong [117] 7% (8/113) Vietnam 2015
Malhotra [118] 33.5% (88/262) India 2016
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infections and access-related bloodstream infections instead 
of HCV infection alone. An audit from nine dialysis units 
in Spain reported that health workers used gloves on 92.9% 
of occasions, hands were washed only in 35.6% of the time 
after patient contact, and only in 13.8% of the time before 
patient contact [126]. The degree of compliance to hand 
washing practices was evaluated by direct observation of 
hemodialysis staff at work. Poor adherence to hand washing 
was associated with the number of shifts per hemodialysis 
unit per day and with higher patient-to-nurse ratios. Compli-
ance to infection control procedures was greater in the acute 
than chronic hemodialysis facilities [125]. Whether or not 
higher hand hygiene standards promoted by regular audits 
translates in a lower incidence of HCV between hemodialy-
sis patients needs to be clarified.
A big drop in prevalence and incidence rates of HCV 
infection within hemodialysis units has been observed after 
the routine implementation of infection control practices and 
the use of sensitive serological assays. A large survey from 
Belgium revealed a decrease in the prevalence of positive 
anti-HCV serologic status from 13.5% in 1991 to 6.8% in 
2000 [127]. The prevalence rates reported in Table 3 are 
lower in comparison with those noted in 1990s [120]. How-
ever, nosocomial transmission of HCV within hemodialysis 
units is still a health concern all over the world [128–130]. 
As an example, a large number of cases of acute HCV 
infection have been notified to the CDC between 2014 and 
2015- about 36 patients with de novo HCV infection in 19 
different hemodialysis clinics from eight US states [131]. 
According to this evidence, the CDC have again highlighted 
the importance of implementation and adherence to recom-
mended control practices in dialysis settings [132]. The 
role of patient-care practices in the spread of HCV between 
patients on hemodialysis has been emphasized recently. 
Indeed, most epidemiological surveys had collected such 
information by self-reports assessing the extent to which 
some practice-care procedures were conducted. Shimokura 
et al. gathered data on patient-care practices by direct obser-
vation and reported a relationship between the prevalence of 
HCV and specific patient-care practices after adjusting for 
non-dialysis related HCV factors [133]. Reusing priming 
receptacles without disinfection (Odds ratio, 2.3, 95% CI, 
1.4–3.9), handling blood specimens in contaminated areas 
(OR, 2.2, 95% CI, 1.3–3.8), and using mobile carts to deliver 
intravenous medications (OR, 1.7; 95% CI; 1.0-2.8) were 
associated with greater prevalence of anti-HCV antibody 
[134].
Statement 5.2  Isolation of hemodialysis patients with HCV 
infection is not suggested.
Rationale
Benefits and arms of isolation for what concerns in-center 
HCV diffusion remain unclear as robust RCTs are missing 
[134]. Isolation strategies were those including a number of 
policies with various grades of intensity, such as using dedi-
cated dialysis machines, staff, room or dialysis shift. Only 
one RCT has been retrieved and concluded that no difference 
was found in terms of incidence of HCV infection when 
comparing the use of dedicated hemodialysis machines 
for HCV infected patients with the use of non-dedicated 
machines [135]. The quality of the evidence provided in 
this RCT was defined very low. Two multicenter, prospec-
tive, observational studies (the DOPPS and the Italian study, 
respectively) both concluded that isolation does not confer 
protection against transmission of HCV between patients 
on regular hemodialysis [136, 137]. A prospective observa-
tional study from Belgium was able to observe a reduction 
in the annual incidence of HCV seroconversion from 1.4 to 
0% after the reinforcement of universal and hemodialysis-
specific practices, without any isolation measures [138]. 
Identical results have been reported in a single-center trial 
from Italy [139].
Convincing arguments against the isolation of HCV-
infected patients on maintenance hemodialysis exist. The 
infectivity of HCV is lower than that of HBV, related at least 
in part to a lower viral load and lack of viability of HCV at 
room temperature. The adoption of an isolation strategy to 
prevent transmission of HCV includes the possibility of an 
Table 4  Relevant infection 
control practices for control of 
HCV within dialysis units
Universal (Standard) precautions
Infection control procedures unique to the hemodialysis setting
 No supplies, instruments, or medications should be shared between patients
 Clear separation between clean and contaminated areas
 Cleaning and disinfection of non-disposable items, environmental surfaces, and dialysis machines 
between uses
Screening for HCV
 Anti-HCV testing (should be repeated semi-annually), ALT testing (should be repeated monthly) for 
susceptible patients
Infection control training and education
Regular audits to ensure improved adherence to recommended practice
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increased risk of HCV infection with more than one gen-
otype. The clinical impact related to infection by various 
strains of HCV remains to be evaluated. Current tests for 
detecting HCV based on antibody screening become positive 
after a serologically silent window (seroconversion time) 
which can last up to 1 year. Isolating patients on regular 
hemodialysis on the basis of HBV and HCV serologic status 
would generate 4 separate cohorts with organizational dif-
ficulties and high costs.
In summary, the isolation of HCV-infected dialysis 
patients is not recommended for preventing transmission of 
HCV within dialysis units. However, a local isolation policy 
for HCV-infected dialysis patients should be considered in 
dialysis units where nosocomial transmission of HCV con-
tinues to occur despite reinforcement and audit of infection 
control procedures designed to prevent transmission of 
blood-borne pathogens, including HCV. In any case, isola-
tion should not be considered an alternative to the imple-
mentation and adherence to the practices recommended in 
dialysis units.
Statement 5.3  Dedicated dialysis machines for hemo-
dialysis patients with HCV are not 
recommended.
Rationale
Data regarding the contamination of the ultrafiltrate or 
dialysate during hemodialysis sessions or peritoneal dialysis 
by anti-HCV positive patients are controversial [140]. From 
a theoretical point of view, we cannot exclude passage of 
virions through the dialyzer membrane of an infected patient 
with migration from the drain tubing to the fresh dialysate 
circuit theoretically allowing the virus to pass through the 
dialyzer membrane to infect another patient; however, the 
occurrence of back-filtration in the second hemodialysis ses-
sion is needed. Such a theoretical process seems unlikely in 
single-pass dialysis machines. Sharing contaminated hemo-
dialysis machines was cited in some reports but the great 
majority of the studies addressing this topic have excluded 
transmission of HCV by internal contamination of dialysis 
machine. External contamination of hemodialysis machines 
is considered an important modality of transmission of HCV 
within hemodialysis; an incomplete disinfection of external 
machine surfaces and other surfaces at the station is a fre-
quent finding in many outbreak reports [120].
Statement 5.4  Chronic hemodialysis patients should be 
screened for anti-HCV antibody at admis-
sion or re-admission to the dialysis center. 
Susceptible hemodialysis patients should 
be tested for HCV antibody twice a year. 
Screening should be anticipated in case of 
signs or symptoms of liver disease (ie liver 
enzymes elevation) and/or in case of occur-
rence of HCV infection in another patient 
the same dialysis center.
Rationale
Anti-HCV screening is essential for identifying outbreaks of 
HCV within hemodialysis units; in fact, HCV infection in 
dialysis patients is usually asymptomatic but routine sero-
logical tests performed serially over time are able to detect 
serologic conversion and appearance of anti-HCV antibody. 
The identification of an outbreak of HCV infection among 
hemodialysis patients should immediately promote an action 
including the assessment of adherence to standard and dialy-
sis-specific infection control procedures; proper screening of 
hemodialysis patients susceptible to HCV should be estab-
lished. In the majority of cases, serologic conversion for 
anti-HCV antibody in a patient on regular hemodialysis is 
related to the dialysis environment and this should require to 
conduct a thorough root cause analysis of the infection and 
address infection control lapses.
The blood for HCV-RNA or HCV Ag testing should be 
drawn prior to a hemodialysis session, because the intradia-
lytic reduction of HCV RNA titers during the hemodialysis 
procedure [141] and the presence of heparin in the blood 
could lead to a false-negative PCR result. The intradialytic 
reduction of HCV RNA during the session could explain 
why the HCV viral load in the dialysis population is not high 
and does not increase over time despite the immune com-
promise conferred from uremia [142]. Adsorption of HCV 
onto dialysis membrane, HCV escape into spent dialysate, 
destruction of HCV particles or increased interferon (IFN) 
activity during the dialysis session represent the main mech-
anisms explaining the reduction of HCV RNA during hemo-
dialysis. A gradual return to pre-dialysis levels within 48 h 
has been also found [142].
We recommend repeat screening of hemodialysis patients 
who are not infected with HCV (anti-HCV antibody nega-
tive) twice a year, in order to detect new infections by HCV. 
Hemodialysis patients with risky sexual intercourses should 
be screened more frequently. In addition, patients who are 
anti-HCV antibody positive/HCV RNA negative (patients 
with resolved HCV infection) require periodic screen-
ing (twice a year) as they remain at risk for re-infection if 
exposed. The identification of new infection could represent 
transmission of HCV within the dialysis center.
When a new HCV infection is identified in a hemodialy-
sis unit, all NAT negative patients within the dialysis unit 
should be tested for HCV infection and the frequency of 
subsequent HCV testing be increased. HCV testing should 
be performed with NAT techniques.
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CDC recommends that all maintenance hemodialysis 
patients be screened for ALT level upon admission and ALT 
testing be repeated monthly for susceptible patients. Serum 
ALT levels fall frequently in the range of normal values; 
however, the majority of hemodialysis patients with de novo 
HCV infection have higher aminotransferase values [143]. If 
an unexplained elevation of ALT occurs, the patient should 
be tested for HCV infection. The exact predictive value of 
ALT screening for detecting HCV infection is unclear [144]. 
Due to the asymptomatic course of HCV infection among 
patients on maintenance dialysis, ALT levels have been fre-
quently used retrospectively to define the likely exposure 
period for patients who acquired infection.
Treatment of chronic hepatitis C virus in CKD 
patients
Statement 6.1  Combination of different classes of directly 
acting antivirals, by acting on different sites 
of the HCV replication cycle, is essential to 
obtain a sustained virological response.
Rationale
Treatment of HCV is based on DAAs, i.e., drugs targeting 
the virus replication cycle [145, 146]. These drugs target 
key steps of HCV replication: the polyprotein cleavage by 
the NS3 Protease (Protease inhibitors, PIs), the HCV RNA 
strain synthesis (NS5B Polymerase inhibitors, of two sorts, 
nucleoside analogues (NA) and non-nucleosides) and the 
stabilization of the replication complex and viral release 
(NS5A inhibitors) [89, 147]. Combination of different 
classes of DAA is essential to obtain a sustained virologi-
cal response defined as HCV RNA undetectability 12 weeks 
after the end of therapy (SVR 12). Although SVR 12 rates 
in the 90–95% range are now achievable in most patient 
populations, patients with CKD still represent a group of 
patients, which requires expert management mainly because 
kidney function affects the Pharmacokinetics of Sofosbuvir, 
an NS5B NA that represents a key backbone of several DAA 
combination regimens.
DAA combinations are essential to maximize SVR rates. 
Currently two DAA combination strategies can be described:
1. The Sofosbuvir based regimens, which include
(a) the combination of Sofosbuvir plus a PI (Sime-
previr),
(b) the combination of Sofosbuvir plus an NS5A 
inhibitor (Velpatasvir, Ledipasvir, Daclatasvir)
(c) the combination of Sofosbuvir plus a PI and an 
NS5A (Velpatasvir/Voxilaprevir)
2. The non-Sofosbuvir based regimens, which include
(a) the combination of a PI plus an NS5A and a non-
nucleoside NS5B inhibitor (Ritonavir boosted 
Pariptarevir/Ombitasvir + Dasabuvir)
(b) the combination of a PI and an NS5A inhibitor 
(Grazoprevir/Elbasvir and Glecaprevir/Pibrentas-
vir)
In this paper we will not analyze all available DAA 
regimens [89, 148], but rather concentrate only on DAA 
regimens currently reimbursed by the Italian National 
Health System, thus excluding the combinations of Sofos-
buvir + Simeprevir, Sofosbuvir + Daclatasvir, Sofosbuvir/
Ledipasvir and Sofosbuvir/Velpatasvir/Voxilaprevir.
Although, some of these regimens are pangenotypic, 
which means they are active against all six HCV strains, 
most of them are restricted in activity to specific genotypes 
(Table 5).
In this paper we will concentrate only on DAA regimens 
currently reimbursed by the Italian National Health System, 
thus excluding the combinations of Sofosbuvir + Sime-
previr, Sofosbuvir + Daclatsvir, Sofosbuvir/Ledipasvir and 
Sofosbuvir/Velpatasvir/Voxilaprevir.




Sofosbuvir should be administered at the dose of 400 mg 
(one tablet) once per day, with or without food. Approxi-
mately 80% of sofosbuvir is renally excreted, whereas 15% 
is excreted in faeces. The majority of the sofosbuvir dose 
recovered in urine is the dephosphorylation-derived nucleo-
side metabolite GS-331007 (78%), while 3.5% is recovered 
as sofosbuvir [89]. Renal clearance is the major elimina-
tion pathway for GS-331007 with a large part actively 
secreted. Thus, currently, no sofosbuvir dose recommenda-
tion can be given for patients with severe renal impairment 
(eGFR < 30 mL/min/1.73 m2) or with end-stage renal dis-
ease due to higher exposures (up to 20-fold) of GS-331007.
Velpatasvir (VEL)
Velpatasvir is metabolised in vitro by CYP2B6, CYP2C8 
and CYP3A4. However, due to the slow turnover, the vast 
majority of drug in plasma is the parent drug. Importantly, 
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velpatasvir is transported by P-glycoprotein (P-gp) and 
breast cancer resistance protein (BCRP) and, to a limited 
extent, by organic anion transporting polypeptide 1B1 
(OATP1B1). Biliary excretion of the parent drug is the 
major route of elimination. The pharmacokinetics of vel-
patasvir was studied in HCV-negative patients with severe 
renal impairment (eGFR < 30 mL/min/1.73 m2). Relative to 
subjects with normal renal function, velpatasvir AUC was 
50% higher and this was not considered to be clinically rel-
evant [89].
Ritonavir boosted Paritaprevir/Ombitasvir ± Dasabuvir 
(PrOD or PrO)
Paritaprevir is an NS3-4A protease inhibitor, which is 
metabolised primarily by CYP3A4 and it is given with a 
low dose of the CYP3A inhibitor ritonavir as a pharma-
cokinetic enhancer. Ombitasvir is an NS5A inhibitor given 
in a fixed-dose combination with paritaprevir/ritonavir. 
The recommended dose of this combination is two tablets 
of ritonavir/paritaprevir/ombitasvir (50 mg/75 mg/12.5 mg 
per tablet) taken orally once daily with food. Dasabuvir is 
a non-nucleoside inhibitor of HCV RNA-dependent RNA 
polymerase in 250 mg tablets administered twice daily in 
combination with ritonavir/paritaprevir/ombitasvir in geno-
type 1 patients. Paritaprevir is excreted predominantly into 
the feces. Ombitasvir shows linear kinetics and it is predomi-
nantly eliminated in the feces. Dasabuvir is metabolized in 
the liver, and its predominant metabolite is mainly cleared 
via biliary excretion and fecal elimination with minimal 
renal clearance [89].
The AUC of paritaprevir was increased 45% in patients 
with severe renal impairment (creatinine clearance 
15–29 mL/min), that of ritonavir 114%, and dasabuvir 50%. 
Currently, no dose adjustment is required for patients with 
mild, moderate or severe renal impairment.
Grazoprevir/Elbasvir (GZR/EBR)
Grazoprevir and elbasvir are available in a two-drug fixed-
dose combination containing 100 mg of grazoprevir and 
50 mg of elbasvir in a single tablet. The recommended dose 
of the combination is one tablet taken orally once daily 
with or without food. Grazoprevir and elbasvir are partially 
metabolized by CYP3A4, but no circulating metabolites 
are detected in plasma. The principal route of elimination 
is biliary and faecal with less than 1% recovered in urine. 
Grazoprevir is transported by P-gp and OATP1B1, while 
elbasvir is a substrate for P-gp.
No dose adjustment is required in patients with mild, 
moderate of severe renal impairment (including patients on 
hemodialysis or peritoneal dialysis). There is an increase in 
elbasvir (65%) and grazoprevir (86%) exposure in non-HCV 
infected subjects with an eGFR < 30 ml/min/1.73 m2, but 
this is not considered to be clinically significant [89].
Glecaprevir/Pibrentasvir (GLE/PIB)
Glecaprevir is a pangenotypic PI and Pibrentasvir is a 
pangenotypic NS5A inhibitor, Glecaprevir/Pibrentas-
vir should be given at dosing of 300 mg/120 mg (three 
100  mg/40  mg tablets), taken orally, once daily with 
food. Glecaprevir and pibrentasvir are weak inhibitors of 
cytochrome P450 (CYP) 3A and uridine glucuronosyltrans-
ferase (UGT) 1A1 in vivo.
Glecaprevir and pibrentasvir AUC were increased ≤ 56% 
in non-HCV infected subjects with mild, moderate, severe, 
or end-stage renal impairment not on dialysis compared 
to subjects with normal renal function. Glecaprevir and 
Table 5  DAA regimens for 
HCV patients according to 
genotype
SOF sofosbuvir, LDV ledipasvir, RBV ribavirin, VEL velpatasvir, PrOD paritaprevir / ritonavir / ombitas-
vir + dasabuvir, EBR Elbasvir, GZR grazoprevir, DCV daclatasvir, SIM simeprevir, GLE glecaprevir, PIB 
pibrentasvir, VOX voxilaprevir
a Indicates regimens reimbursed by Italian NHS
b Reimbursed only in DAA failures
Combination regimen Genotype 1 Genotype 2 Genotype 3 Genotype 4 Genotype 5–6
SOF/LDV ± RBV Yes No No Yes Yes
SOF/VELa ± RBV Yes Yes Yes Yes Yes
PrODa ± RBV Yes No No No No
PrOa± RBV No No No Yes No
EBR/GZRa ± RBV Yes No No Yes No
SOF + DCV ± RBV Yes Yes Yes Yes Yes
SOF + SIM ± RBV Suboptimal No No Yes No
GLE + PIBa Yes Yes Yes Yes Yes
SOF + VEL + VOXb Yes Yes Yes Yes Yes
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pibrentasvir AUC were similar with and without dialysis 
(≤ 18% difference) in dialysis-dependent non-HCV infected 
subjects. In population pharmacokinetic analysis of HCV-
infected subjects, 86% higher glecaprevir and 54% higher 
pibrentasvir AUC were observed for subjects with end stage 
renal disease, with or without dialysis, compared to sub-
jects with normal renal function. Larger increases may be 
expected when unbound concentration is considered.
Overall, the changes in exposures of glecaprevir and 
pibrentasvir in HCV-infected subjects with renal impairment 
with or without dialysis were not clinically significant. No 
dose adjustment of glecaprevir and pibrentasvir is required 
in patients with any degree of renal impairment including 
patients on dialysis [149].
Statement 6.3  In HCV patients with CKD stage 4–5 or 
on hemodialysis, non-Sofosbuvir based 
regimens should be preferred whenever 
possible.
Rationale
As previously discussed sofosbuvir is renally elimi-
nated, in patients with mild to moderate renal impairment 
(eGFR ≥ 30 mL/min/1.73 m2), no dose adjustments are nec-
essary for the combination of sofosbuvir and velpatasvir. 
In patients with CKD stage 4 with severely reduced renal 
function (eGFR 15–29  mL/min/1.73  m2) or those with 
CKD stage 5 (eGFR < 15 mL/min/1.73 m2 or on dialysis) 
there is a lack of properly conducted trials on sofosbuvir 
based regimens. Concerns have been raised because of the 
substantially higher concentrations of sofosbuvir and, most 
importantly, of its renally excreted metabolite GS-331007 
(+ 171% and + 451% AUC 0–inf, respectively, as compared 
with patients without renal impairment). The appropriate 
therapeutic dose of sofosbuvir in patients with advanced or 
end-stage renal disease is not established. For this reason, 
in HCV patients with CKD stage 4–5 sofosbuvir-free regi-
mens should be preferred whenever possible [89]. No dose 
adjustment is required in CKD patients when treated with 
paritaprevir/ombitasvir/dasabuvir, grazoprevir/elbasvir or 
glecaprevir/pibrentasvir. These regimens were investigated 
in ad-hoc clinical trials designed to assess the safety and the 
efficacy in CKD stage 4–5. In the Ruby-1 trials 20 HCV-1 
patients without cirrhosis with stage 4 or stage 5 CKD 
received 12 weeks of paritaprevir/ombitasvir/dasabuvir, 
the 13 patients infected with genotype 1a received ribavirin 
200 mg once daily. The SVR12 rate was 90% (18/20) [150].
In the C-SURFER trial, 122 patients infected with HCV 
genotype 1 with CKD stage 4 or 5 received grazoprevir and 
elbasvir for 12 weeks without ribavirin. The SVR12 rate 
was 94% (115/122), with only one virological failure. The 
frequencies of renal system adverse events were generally 
comparable between treatment groups [151]. In the Expe-
dition-4 Trial 104 HCV patients with CKD stage 4–5 of 
any genotype received 12 week of Glecaprevir/Pibrentasvir 
the sustained virologic response rate was 98% (102 of 104 
patients; 95% confidence interval, 95 to 100). No patients 
had virologic failure during treatment, and no patients had 
a virologic relapse after the end of treatment [152].
Statement 6.4  In HCV patients with CKD, Ribavirin free 
schedules should be preferred.
Rationale
Table 6 shows the optimal duration and schedules of par-
itaprevir/ombitasvir/dasabuvir, grazoprevir/elbasvir or 
glecaprevir/pibrentasvir in HCV patients with CKD stage 
4–5. Although no direct comparison of these regimens 
Table 6  Optimal duration and schedules of DAA regimens for HCV patients with CKD stage 4–5
Paritaprevir/ombitasvir/dasabuvir (PrOD), grazoprevir/elbasvir (GZR/EBR) or glecaprevir/pibrentasvir (GLE in HCV patients with CKD stage 
4–5)
PrOD paritaprevir/ritonavir/ombitasvir/dasabuvir, GZR/EBR grazoprevir/elbasvir, GLE/PIB glecaprevir/pibrentasvir
a 24 weeks in patients with Child-Turcotte-Pugh class A cirrhosis
b 16 weeks in patients with HCV RNA > 800.000 IU/mL or NS5A RAS
c 12 weeks in patients with Child-Turcotte-Pugh class A cirrhosis
d 16 weeks in patients with a previous failure to PegIFN or SOF
Combination regimen Genotype 1a Genotype 1b Genotype 2 Genotype 3 Genotype 4 Genotype 5–6
PrOD ± RBV 12–24a weeks
+ RBV
12 weeks No No No No
PrO ± RBV No No No No 12 weeks
+ RBV
No
GZR/EBR ± RBV 12–16  weeksb
± RBV
12 weeks No No 12–16  weeksb
± RBV
No
GLE/PIB 8–12c weeks 8–12c weeks 8–12c weeks 8–16c,d weeks 8–12c weeks 8–12c wks
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exists, ribavirin-free schedules should be preferred due 
to accumulation of ribavirin in the blood of patients with 
kidney impairment leading to increased rates on anemia 
and treatment related side effects [153]. In addition, the 
removal of ribavirin by the hemodialysis procedure is 
poor. If ribavirin has to be used, individualized ribavi-
rin dosing of 200 mg/day or 200 mg/every other day or 
200 mg thrice weekly after hemodialysis is recommended, 
and substantial hematopoietic support is essential [89].
Clinical trials and real-life data clearly showed that 
also in patients with CKD therapeutic regimens based on 
DAA are safe and without significant side effects, even 
if patients treated with ribavirin and/or patients with 
advanced liver and/or kidney disease should be carefully 
followed.
Statement 6.5  In certain conditions, sofosbuvir-based 
regimens and ribavirin can be considered 
but risk–benefit ratio must be carefully 
weighed.
Rationale
There are conditions such as in Child-Pugh-Turcotte class 
B-C patients or those with significant drug–drug inter-
actions in whom paritaprevir/ombitasvir/dasabuvir, gra-
zoprevir/elbasvir or glecaprevir/pibrentasvir are unsafe 
or contraindicated. In these cases, the combination of 
sofosbuvir/velpatasvir for 12 weeks ± Ribavirin can be 
considered. Ribavirin should be given in HCV-3 infected 
patients with cirrhosis or in those without cirrhosis who 
have failed a previous IFN course [89]. The data on sofos-
buvir based regimens in CKD patients are scanty and 
mostly derive from small cohort studies, which included 
heterogeneous groups of patients with different etiologies 
of kidney diseases and various degrees of liver disease 
staging [154, 155]. Consistently across all cohorts, the 
efficacy of sofosbuvir-based regimens is not reduced by 
the presence of CKD; however, conflicting results exist 
in terms of safety signals. In the TARGET 2.0 real-world 
cohort study, progressive deterioration of renal function 
and renal symptoms were reported in patients with severe 
renal impairment receiving a sofosbuvir-based regimen, 
while others, including a recent meta-analysis, have not 
confirmed this finding [154–156]. Thus if treatment is 
urgent and no sofosbuvir-free regimen is available, the 
risks versus the benefit of sofosbuvir-based regimens 
should be carefully weighed. Close monitoring is required 
and treatment should be rapidly interrupted if the kidney 
damage worsens, as testified by either sudden renal func-
tion decline or onset/worsening of albuminuria [89].
HCV and kidney transplantation
Statement 7.1  The prevalence of HCV infection in kidney 
transplant recipients (KTRs) is high. Kid-
ney transplant is the better therapeutic strat-
egy for patients with ESRD and HCV infec-
tion. However, HCV infected KTRs have 
worse clinical outcome than non-infected.
Rationale
The prevalence of HCV infection in kidney transplant 
recipients is high with an estimated a prevalence of 
patients HCV positive of 6.8% [157].
Kidney transplantation is reportedly the better treatment 
for ESRD patients with HCV infection. A meta-analysis 
that evaluated nine controlled studies selected from the 
378 available on the topic, showed better survival in HCV 
infected patients undergone kidney transplantation as com-
pared to those who remained on the waiting list [158].
CV disease remains the first cause of death in HCV 
patients still on dialysis, whereas both CV and infectious 
diseases accounted for mortality in the group of transplanted 
patients. It is conceivable that restored kidney function with 
improved clearance of uremic toxins, together with reduced 
inflammatory status and oxidative stress may have contrib-
uted to the better survival rate of transplanted patients [159]. 
Furthermore, regression of left ventricular hypertrophy, 
reported after successful kidney transplantation, may play a 
role in the decreased CV mortality [160].
However, general transplant outcome of HCV patients is 
worse than that of non-infected KTRs mainly due to elevated 
cardiovascular morbidity, increased incidence of post-trans-
plant diabetes and infectious diseases, and to liver disease 
progression, including cirrhosis and hepatocellular carci-
noma [161, 162]. A recent analysis based on the long-term 
outcome of 33,357 KTRs, found that, among 1470 HCV 
positive KTRs, HCV was associated with higher risk of 
death and graft failure. Infection, liver failure and recurrent 
disease were more common causes of death in HCV positive 
KTRs than in HCV negative [163, 164].
Although post-transplant immunosuppressive ther-
apy has a permissive effect on liver fibrosis progression 
through interference with HCV-driven inflammatory 
milieu, clinical data has shown reduced progression or 
even partial reversal of liver fibrosis in HCV infected 
patients after kidney transplantation as compared to those 
who remained in the waiting list [161].
Last, de novo disease of kidney graft related to 
HCV infection, and greater occurrence of transplant 
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glomerulopathy may contribute to the poorer outcome 
observed in KTRs with HCV infection [164].
Statement 7.2  DAA therapy is effective and safe in HCV 
infected  kidney transplant recipients. 
Treatment schedule and duration should 
be performed according available guide-
lines taking account of liver fibrosis stage, 
HCV genotype, renal function and drug 
interactions.
Rationale
Traditional anti-viral therapy with IFN and ribavirin in renal 
patients was burdened by low SVR (about 35%) and elevated 
dropout ratio [165]. Remarkably, the immuno-stimulating 
property of this cytokine was associated with significantly 
higher rates of acute rejection and worsening of kidney graft 
function in more than 50% of patients treated with IFN. 
Thus, the panel of KDIGO released a warning about the 
adoption of such a therapy after kidney grafting [88] and 
viral eradication had been generally suggested in dialysis 
patients waiting for a kidney transplant [166].
By contrast, new available DAA proved to be as effective 
as safe in KTRs; sustained virological eradication is reported 
in 90–100% of cases, with low ratio of significant adverse 
events, while graft function remained stable during treat-
ment in most studies [154, 167–175]. Table 7 presents data 
on the available studies with DAA in KTRs.
A sofosbuvir-based anti-viral therapy was used in most 
studies. Colombo et al. conducted an open-label clinical trial 
and evaluated the safety and efficacy of the daily fixed-dose 
combination of ledipasvir (90 mg)/sofosbuvir (400 mg) in 
114 genotype 1–4 kidney transplant recipients with median 
eGFR ranging from 50 to 60 mL/min [172]. Overall SVR12 
was 100% and safety profile was good. A slight eGFR reduc-
tion was reported (between − 0.6 and − 0.3 mL/min) and 
11% of the patients experienced adverse events, leading to 
treatment discontinuation in only one patient.
Several additional reports have described successful out-
comes by using sofosbuvir-based regimens in kidney trans-
plant recipients [154, 170–173, 175, 176].
However, approximately 80% of sofosbuvir is excreted 
by renal route in form of dephosphorylation-derived nucleo-
side metabolite GS-331007 [89]. Due to the higher exposure 
(up to 20-fold) to GS-331007, special cautions should be 
adopted in KTRs, especially in those with uncomplete recov-
ery of renal function after transplantation [177].
The phase 3, open-label MAGELLAN-2 study evaluated 
a 12-week course of the pangenotypic regimen glecaprevir/
pibrentasvir in 20 KTRs [174]. A high rate of SVR was 
confirmed as well as its safety profile. The extent of the drug 
interaction with calcineurin inhibitors (see Statement 7.4) 
and the need of therapeutic drug monitoring is counterbal-
anced by the fact that this regimen can be used independ-
ent of renal function, as renal excretion is not the preferred 
mechanism of elimination.
Overall, these studies confirmed the high rate of viral 
eradication also in the setting of kidney transplantation with-
out significant incidence of graft rejection. Notwithstanding, 
a trend toward decrease in CNI trough levels has also been 
reported in most studies dealing with sofosbuvir-based DAA 
therapy in KTRs with the need of CNI dose adjustment after 
beginning DAA therapy [177]. Recently, Fernandez-Ruiz 
focused on the impact of sofosbuvir-based regimens on the 
pharmacokinetics of immunosuppressive drug levels in 49 
KTRs and observed marked increased in dose requirements 
of calcineurin inhibitors (CNI) and everolimus to main-
tain blood concentrations as well as a significant decrease 
in eGFR and increase of proteinuria during the first year 
after treatment [176]. The possibility that HCV clearance, 
as described in other settings, could paradoxically favor 
alloimmune-mediated injury or that abnormal tacrolimus 
pharmacokinetic could lead to drug underexposure are the 
most attractive hypotheses and deserves peculiar care also 
during mid-term post eradication follow up [178].
Statement 7.3  Timing of DAA therapy—i.e. to treat before 
or after kidney grafting- should be individ-
ualized in each patient, by balancing indi-
vidual clinical conditions and the need to 
shorten time on waiting list. The decision 
to delay treatment after kidney transplant 
must take into account the availability of 
active national program for the allocation 
of HCV positive organs.
Rationale
The better timing of DAA therapy for KTRs (before grafting 
or after successful kidney transplantation) remains a still 
unresolved issue [179]. Recent studies in ESRD patients 
with genotype 1 or 4 HCV infection receiving either grazo-
previr/elbasvir [151], or ombitasvir/paritepravir/dasabuvir 
[150], have shown SVR in the majority of dialysis patients 
with a good safety profile. New options for these patients 
comes from the multicenter, open label, phase-3 trial with 
the pangenotypic combination of glecaprevir/ pibrentas-
vir for 12 weeks [152]. Among 104 patients with severe 
renal impairment and/or dependence on dialysis, SVR rate 
was 98%. Adverse events and serious adverse events were 
reported in 24% and 10% of the patients respectively lead-
ing to treatment discontinuation in four cases (3.8%) [152]. 
Overall, treating ESRD patients before kidney transplanta-
tion seems to be a good opportunity, by possibly avoiding 
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detrimental interference of DAA with immunosuppressive 
agents in the post-transplant setting.
However, this strategy exclude HCV+ patients on dialy-
sis from the program of kidney transplantation from HCV 
infected donors  (D+R+). In fact, HCV+ transplant candi-
dates who were not treated while on the waiting list have 
the option of listing for a HCV+ kidney allocation. The 
individual benefit gained from this policy is that it reduced 
patients’ time on the deceased donor waiting list owing 
the relatively few patients competing for a HCV+ kid-
ney. In a study of the UNOS database from 1995 to 2009, 
Kucirka et  al. found that recipients of HCV+ kidneys 
waited 310 days fewer than the average waiting times at 
Table 7  Studies that have evaluated DAAs in kidney transplant recipients (KTRs)
SOF sofosbuvir, SMV simeprevir, LDV ledepasvir, GLE/PIB glecaprevir/probentasvir, RBV ribavirin, PrOD paritaprevir/ritonavir/ombitas-
vir + dasabuvir, eGFR estimated glomerular filtration rate, TAC tacrolimus, CNI calcineurin inhibitors, SVR sustained virologic response
a Data available only in abstract form
Author [reference] Year Patients (Genotype) Therapy Duration (weeks) SVR (%) Adverse events Graft function
Kamar [167] 2015 25 KTRs (76% 
genotype 1)
SOF-based 12–24 100 None 3 pts had eGFR 
decline ≥ 10 mL/
min
Decrease in TAC TL
Sawinski [168] 2016 20 KTRs (88% 
genotype 1)
SOF-SMV 12 100 None Stable graft function
45% required CNI 
dose adjustment
Lin [169] 2016 24 KTRs (58% 
genotype 1a)




2 pts (8.3%) required 
CNI dose adjust-
ment
Beinhardt [170] 2013 8 KTRs (genotype 
1,4)
SOF-based 12 100 50%, no severe AEs Stable graft function
1 pt (12.5%) required 
CNI dose adjust-
ment
Lubetzky [171] 2017 31 KTRs (90% 
genotype 1)
SOF + LDV 12–24 97 None Stable graft func-
tion in all but 
2 pts whose 




Colombo [172] 2017 114 KTRs (geno-
type 1,4)
SOF + LDV 12–24 100 11% eGFR decline from




Morales [173] 2017 32 KTRs (91% 
genotype 1)
SOF + LDV 8–24 96 1 borderline rejec-
tion; 4 unrelated 
deaths
25% CNI dose 
adjustement
Stable graft function
Reaua [174] 2017 20 KTRs (genotype 
1–6)
GLE/PIB 12 98 Rare (1 sinusitis, 1 
hepatic abnor-
mality)
Slight reduction in 
TAC doses needed
Fernandez [175] 2017 103 KTRs (83% 
genotype 1)
SOF-based ± RBV 
(n = 93)
PrOD ± RBV 
(n = 10)
12–24 98 3 rejection; 55% 
CNI dose adjuste-
ment
16% increase in 
creatinine
Saxena [153] 2017 60 KTRs (90% 
genotype 1)
SOF based 12–24 94.5 2 rejection No specific data
Fernandez-Ruiz 
[176]




12–24 95.8 none Significant decline in 
eGFR in the post-
SVR follow-up 
period
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their center and 395 fewer days than counterparts who 
waited for HCV negative kidneys [180].
Excellent long-term results in terms of both patients 
and graft survival were also reported in a study that evalu-
ated 195 HCV positive patients who received graft from 
HCV+ donors, as compared with 66 HCV+ receiving trans-
plant from ideal HCV negative donors [181]. However, 
this program is weakened by the high rate of discard rate 
of HCV+ organs. McCauley et al., reported that only 37% 
of available HCV+ kidneys were transplanted from 2005 to 
2014, with a discard rate of 67% compared to a usual rate 
of 20% for ideal organs [182]. Moreover, benefits result-
ing from the HCV+ for HCV+ program must be weighed 
against several concerns for transplanting HCV+ kidneys 
into HCV+ recipients. These concerns historically included 
the nearly universal transmission of the virus and the pos-
sible genotype superinfection as well as inferior patient and 
graft survival in patients who receive HCV+ compared to 
HCV− kidneys.
While the program HCV+ for HCV+ was associated with 
good results in the United States, data from Italian Trans-
plant Registry are quite different with less than 1% of the 
total 10-year kidney transplants performed in HCV+ recip-
ients from HCV+ donors according to the National 2015 
Registry. This scenario probably reflects previous con-
cerns about interferon application after transplant and it is 
expected to change substantially in the short-term period 
in view of the ability to treat efficiently HCV post-trans-
plantation. Recently, the Italian National Center for Organ 
Transplantation has released official Italian guidelines for 
the utilization of HCV positive organs for transplantation 
(Fig. 2). Only systematic application of these rules could 
leads to actual improvement in kidney transplant rate with 
HCV+ organs, thus counterbalancing the concerns about the 
effectiveness of such a strategy.
However, the survival advantages of kidney transplant 
compared to dialysis patients strengthens the argument for 
delaying DAA treatment and listing for a HCV+ kidney. In 
a study by Sawinski et al., who hypothesize an algorithm for 
managing pre-transplantation patients with HCV, patients 
who received HCV+ kidneys waited approximately 484 days 
(1.3 years) significantly fewer than those who received 
HCV- kidneys [183].
Finally, two recent reports have shown good results of 
DAA therapy performed after kidney transplantation [184, 
185]. SVR was obtained in 96% of HCV+ patients who 
received HCV+ kidneys and started DAA therapy in early 
post-transplant (median 125 days) [184] and in 100% of 
HCV negative ESRD subjects who received HCV+ kidneys 
receiving DAA therapy performed immediately after graft-
ing [185]. These findings confirm that availability of DAA 
have definitely changed our perspectives in the management 
of HCV infected patients with ESRD.
In view of the association between HCV positivity and 
some specifically related conditions after kidney transplan-
tation (diabetes, transplant glomerulopathy etc), data on 
the overall effects of treating HCV post-transplantation on 
patient and graft survival are warranted.
In the meanwhile, it appears wise to individualize treat-
ment timing and schedules according to clinical criteria on 
the basis of availability of local organization favoring HCV 
positive donation.
Statement 7.4  DAA in kidney transplant recipients must be 
managed under strict collaboration between 
nephrologists and hepatologist. Careful 
baseline assessment of the degree of renal 
function, liver fibrosis staging, HCV geno-
types, immunosuppressive schemes and 
concomitant therapies could safely address 
the choice of antiviral drug.
Rationale
The concomitant treatment with DAA and immunosuppres-
sive drugs could expose the patients to drug–drug interac-
tions (DDI) that should be actively prevented by correctly 
choosing therapeutic regimens, monitoring their effects dur-
ing therapy and, when appropriate, performing therapeutic 
drug monitoring (TDM). The need to monitor immunosup-
pressive agent levels during DAA therapy, in fact, is high-
lighted by the observational HCV-TARGET cohort study: 
acute graft rejection occurred during or after cessation of 
therapy in 1.4% (6/415) of patients [154]. Although it is not 
clear if these episodes are a direct effect of the antiviral regi-
men, an accurate surveillance of the patients is mandatory.
The DDIs between sofosbuvir-based DAA treat-
ments and immunosuppressive drugs (CNI, tacrolimus, 
Fig. 2  Italian National guidelines for the evaluation of the eligibility 
of solid organ donors as per the State-Regions Conference (version 
1.0; February 23, 2017)
705Journal of Nephrology (2018) 31:685–712 
1 3
everolimus) have been previously described (Statement 
7.2). In choosing the most appropriate associations of 
DAA and immunosuppressive agent, we should also con-
sider that cyclosporine and tacrolimus increase daclatasvir 
area under the curve (AUC) by 40% and 5%, respectively 
although these changes are not clinically significant. On 
the other hand, daclatasvir does not cause clinically mean-
ingful changes in CNI, mammalian target of rapamycin 
(mTOR) inhibitor, steroid, or mycophenolate levels. In 
healthy volunteers, coadministration of a single dose of 
cyclosporine with simeprevir resulted in a 19% increase 
in cyclosporine concentration and simeprevir concentra-
tion similar to historical data [186]. Moreover, the phase 
2 SATURN study reported that HCV-infected liver trans-
plant recipients with genotype 1b infection taking sime-
previr plus daclatasvir and ribavirin concomitantly with 
cyclosporine experienced a five-fold increase in plasma 
simeprevir exposure compared with phase 3 trials of 
simeprevir in the absence of cyclosporine [187]. This 
interaction may be caused by cyclosporine’s inhibition 
of OATP1B1, P-gp, and cytochrome P450 3A (CYP3A). 
Given these findings, simeprevir should not be coadmin-
istered with cyclosporine.
Coadministration of a single dose of tacrolimus with 
simeprevir in healthy volunteers did not result in a notable 
change in tacrolimus concentration [186]. Conversely, an 
interim analysis of the SATURN study data noted an 85% 
increase in plasma simeprevir exposure when used concomi-
tantly with tacrolimus compared with historical data [187, 
188]. Based on phase 1 studies, a two-fold increase in sime-
previr concentration is unlikely to be clinically significant. 
Clinicians may consider use of sofosbuvir plus simeprevir 
in patients receiving tacrolimus with TDM, particularly in 
those expected to be unsuitable for ribavirin (eg, patients 
with impaired renal function or anemia) or in patients who 
are proton pump inhibitors dependent, as these agents atten-
uate ledipasvir absorption.
Velpatasvir is a substrate for CYP3A4, CYP2C8, and 
CYP2B6, a weak inhibitor of P-gp and OATP transporters, 
and a moderate inhibitor of the BCRP membrane transporter. 
As such, velpatasvir is moderately affected by potent inhibi-
tors and, to a greater extent, by potent inducers of enzyme/
drug transporter systems [189]. Based on this profile, which 
is similar to ledipasvir, clinically significant drug–drug inter-
actions would not be expected for co-administration of sofos-
buvir/velpatasvir with common immunosuppressive agents 
(eg, tacrolimus, cyclosporine, corticosteroids, mycopheno-
late mofetil, or everolimus). Based on the metabolism of gra-
zoprevir and elbasvir, a 15-fold increase in grazoprevir AUC 
and a two-fold increase in elbasvir AUC can be expected 
with cyclosporine co-administration. Therefore, this com-
bination should be avoided. Since a 40–50% increase in 
tacrolimus level is predicted during co-administration with 
grazoprevir, no dosing adjustments seem to be required, but 
tacrolimus levels should be carefully monitored.
Glecaprevir and pibrentasvir are inhibitors of P-gp, 
BCRP, and OATP 1B1/3 and a weak inhibitors of CYP P450 
3A and UGT 1A1 in vivo. Other significant inhibitions are 
not expected. Cyclosporine inhibits P-gp and BCRP and 
a five-fold increase of glecaprevir AUC is expected with 
higher doses cyclosporine. Consequently, this regimen 
is not recommended for use in patients requiring stable 
cyclosporine doses > 100 mg per day. If the combination is 
unavoidable, however, use can be considered if the benefit 
outweighs the risk adopting a close clinical monitoring. By 
contrast, a moderate 1.45-fold increase in tacrolimus AUC 
is expected. Therefore, the combination of glecaprevir/
pibrentasvir with tacrolimus should be used considering an 
accurate therapeutic drug monitoring of tacrolimus and an 
accordingly dose adjustment [190].
In summary, the interaction of DAA agents and CNI 
is complex and unpredictable without available studies of 
DDIs. A summary of drug interactions between CNI and 
DAA with recommended dosing is provided in Table 8.
Particular attention should be addressed to the special 
population of HIV/HCV co-infected KTRs, where the DDI 
surveillance must include also the antiretroviral regimens. 
In these patients, DAA regimens and/or antiretroviral drug 
switches, when needed, should be planned in a multidisci-
plinary fashion including the nephrologist, the hepatologist 
and the HIV specialist.
The use of the online drug interaction charts by the 
Department of Pharmacology at the University of Liverpool 
is therefore strongly encouraged [191, 192].
Conclusion
A strict collaboration among different healthcare profes-
sional involved in the care of CKD patients with HCV infec-
tion is mandatory in order to timely identify this popula-
tion and tailor the most appropriate treatment based on the 
patient’s clinical condition. To this aim, we recommend the 
multidisciplinary approach reported in Fig. 3. Nephrologist 
must screen all patients at their first visit for HCV infection 
with anti-HCV Ab assay. In those positive, a viral load must 
be required with, possibly, the determination of the HCV 
genotype. Once nephrologist has completed the staging of 
CKD, the patient must be sent to hepatology consultation 
to perform staging of hepatic disease and evaluate eligibil-
ity to DAA treatment. The choice of DAA to administer 
remains in charge to the hepatologist, but discussion with 
nephrologist about concurrent therapy, renal involvement 
and comorbidities is recommended in order to better select 
the most appropriate DAA regimen. Monitoring of DAA 
response remains a specific competence of hepatologist 
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but he/she is required to include in the panel of laboratory 
data at least serum creatinine and albuminuria, measured 
as either dipstick, albumin/creatinine ratio on morning void 
or 24-h excretion. In the presence of signal of acute renal 
damage (increase of serum creatinine > 0.3 mg/dL and/or 
presence or worsening of albuminuria), hepatologist must 
refer the patient to the nephrologist to confirm diagnosis of 
AKI and eventually to implement specific treatment.
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